

Product Data Sheet

PD-1 Protein, Human (C93S, HEK293, His)

Cat. No.: HY-P70799

Synonyms: Programmed cell death protein 1; PDCD1; PD-1; hPD-1; CD279

Species: Human HEK293 Source:

Q15116 (L25-Q167,C93S) Accession:

Gene ID: 5133

23-38 kDa Molecular Weight:

PROPERTIES

	_		
ΔΔ	Sea	IIAr	\sim

LDSPDRPWNP PTFSPALLVV TEGDNATFTC SFSNTSESFV LNWYRMSPSN QTDKLAAFPE DRSQPGQDSR FRVTQLPNGR DFHMSVVRAR RNDSGTYLCG AISLAPKAQI KESLRAELRV

TERRAEVPTA HPSPSPRPAG QFQ

Biological Activity

2 μg/mL (100 μL/well) of immobilized Human PD-1-His can bind Anti-Human PD-1 with an ED50 value of 11.55 ng/mL, corresponding to an affinity constant of 4.97 nM.

Appearance

Lyophilized powder.

Formulation

Lyophilized from a 0.2 µm filtered solution of PBS, pH 7.4.

Endotoxin Level

<1 EU/µg, determined by LAL method.

Reconsititution

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Storage & Stability

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Shipping

Room temperature in continental US; may vary elsewhere.

DESCRIPTION

Background

PD-1 protein functions as an inhibitory receptor on antigen-activated T-cells, playing a crucial role in the induction and maintenance of immune tolerance to self. Upon binding to its ligands CD274/PDCD1L1 and CD273/PDCD1LG2, PD-1 delivers inhibitory signals and associates with CD3-TCR in the immunological synapse, directly impeding T-cell activation. This inhibitory action is further executed through the recruitment of PTPN11/SHP-2, leading to the dephosphorylation of key TCR proximal signaling molecules. Exploited by tumors to attenuate anti-tumor immunity, PD-1's interaction with

CD274/PDCD1L1 inhibits cytotoxic T lymphocytes (CTLs) effector function. Blockage of the PD-1-mediated pathway has shown promise in reversing the exhausted T-cell phenotype and normalizing the anti-tumor response, providing a rationale for cancer immunotherapy.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com